12:00 AM
Mar 12, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Varespladib methyl: Development discontinued

Anthera discontinued development of cardiovascular product varespladib due to "lack of efficacy" in the double-blind, placebo-controlled, international Phase III VISTA-16 trial to treat ACS. Anthera made the decision based on a recommendation from the study's DSMB, which reviewed available safety and efficacy data from the trial. VISTA-16 was evaluating once-daily...

Read the full 229 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >